Russell Investments Group
OCUL icon

Russell Investments Group’s Ocular Therapeutix OCUL Stock Holding History

Russell Investments Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.89M Buy
192,322
+39,438
+26% +$357K ﹤0.01% 2131
2026
Q1 		$1.29M Buy
152,884
+58,458
+62% +$557K ﹤0.01% 2092
2025
Q4 		$1.15M Buy
94,426
+80,603
+583% +$979K ﹤0.01% 2153
2025
Q3 		$162K Buy
+13,823
New +$165K ﹤0.01% 2872
2025
Q2 		– Sell
-120
Closed -$880 – 3927
2025
Q1 		$880 Buy
120
+52
+76% +$400 ﹤0.01% 3605
2024
Q4 		$581 Hold
68
– – ﹤0.01% 3591
2024
Q3 		$592 Buy
+68
New +$560 ﹤0.01% 3551
2023
Q1 		– Sell
-13,561
Closed -$38.1K – 3353
2022
Q4 		$38.1K Sell
13,561
-17,382
-56% -$57.5K ﹤0.01% 2756
2022
Q3 		$128K Buy
+30,943
New +$156K ﹤0.01% 2630
2021
Q1 		– Sell
-562
Closed -$11K – 3173
2020
Q4 		$11K Buy
+562
New +$8.35K ﹤0.01% 3002

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Russell Investments Group's OCUL Position: Q2 2026 in Review

Russell Investments Group increased its Ocular Therapeutix (OCUL) stake by 26% in Q2 2026, buying an estimated $357K and bringing the position to 192,322 shares worth $1.89M. The position accounts for ﹤0.01% of the portfolio, ranked #2131.

Russell Investments Group first reported a position in OCUL in Q4 2020 and has held it in 10 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Russell Investments Group held 192,322 shares of Ocular Therapeutix worth $1.89M as of Q2 2026.
  • Russell Investments Group bought 39,438 Ocular Therapeutix shares in Q2 2026, an estimated $357K.
  • Ocular Therapeutix made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2131 holding.
  • Russell Investments Group first reported a position in Ocular Therapeutix in Q4 2020 and has held it in 10 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.